Cardiovascular diseases

Antithrombotic medications

• Apixaban oraal oplosbare film
• Asundexian
• Edaravone / dexborneol

Hemostasis promoting medication

• Fibrinogen

• Turoctocog alfa pegol

  • Extension of indication to include children below 12 years of age for treatment and prophylaxis of bleeding with haemophilia A for Esperoct, including previously untreated patients (PUPs).
• Valoctocogene roxaparvovec

• Vonicog alfa

  • Treatment of haemorrhage in children (aged less than 18 years) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.

Lipid-lowering medications

• Enlicitide decanoate

• Evolocumab

  • Extension of indication to extend the indication for REPATHA to include adults at high risk for a first cardiovascular event.

• Inclisiran

  • Extension of indication to include the treatment of paediatric patients aged 12 to less than 18 years with homozygous or heterozygous familial hypercholesterolaemia (HoFH/HeFH).

• Lerodalcibep

  • Is indicated in adults with primary hypercholesterolaemia (heterozygous familial (HeFH) and non-familial) or mixed dyslipidaemia as an adjunct to diet.
  • Cardiovascular disorder in adults and elderly on a stable diet and oral LDL-C lowering drug therapy with history of CVD, monotherapy for add-on treatment.
• Lomitapide ^IND
• Obicetrapib
• Obicetrapib / ezetimibe

• Olezarsen

  • Olezarsen monotherapy for add-on treatment of severe hypertriglyceridemia in adults and elderly.
  • Tryngolza is indicated as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS).
• Pegozafermine
• Pelacarsen
• Plozasiran

Other medication for cardiovascular diseases

• Acoramidis
• Aficamten
• Baxdrostat

• Eplontersen

  • Transthyretin amyloid cardiomyopathy (ATTR-CM).
• Etripamil

• Finerenon

  • Kerendia is indicated for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) ≥ 40% in adults.
• Fondaparinux Sodium ^BS
• Glutathione Sodium
• Lorundrostat
• Selatogrel
• Seralutinib

• Tafamidis

  • Tafamidis monotherapy for treatment of hereditary Transthyretin amyloid cardiomyopathy in adults.

• Vericiguat

  • Extension of indication for treatment of symptomatic chronic Heart failure with reduced ejection fraction in adults and elderly who have not had a recent hospitalization for heart failure or need for outpatient intravenous diuretics.

• Vutrisiran

  • Amvuttra is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
• Zalunfiban
• Ziltivekimab

Other non-oncological hematological medications

• Anselamimab

• Benralizumab

  • Fasenra is indicated as an add‑on treatment for adult and adolescent patients aged 12 years and older weighing at least 35 kg with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause

• Concizumab

  • Routine prophylaxis of bleeding in patients with; haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors and of 12 years of age or more; haemophilia B (congenital factor IX deficiency) with FIX inhibitors and of 12 years of age or more.
  • Alhemo is indicated for routine prophylaxis of bleeding in patients 12 years of age or more with severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without FVIII inhibitors and moderate/severe haemophilia B (congenital factor IX deficiency, FIX ≤2%) without FIX inhibitors.

• Crovalimab

  • Piasky as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): - In patients with haemolysis with clinical symptom(s) indicative of high disease activity. - In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.
• Danicopan
• Denecimig
• Etavopivat
• Ferrimaltol ^IND
• Giroctocogene fitelparvovec

• Marstacimab

  • Routine prophylactic treatment of bleeding in patients twelve years and older with malignant hemophilia A and B without inhibitors.
  • Hympavzi is geïndiceerd voor routineprofylaxe van bloedingen bij patiënten van 12 jaar en ouder, met een gewicht van ten minste 35 kg, met: ernstige hemofilie A (congenitale factor VIII-deficiëntie, FVIII <1%) zonder factor VIII remmers, of ernstige hemofilie B (congenitale factor IX-deficiëntie, FIX <1%) zonder factor IX-remmers.

• Mitapivat

  • Mitapivat monotherapy for treatment of pyruvate kinase deficiency anaemia in infants and toddlers over 1 year of age, children and adolescents who are not regularly receiving blood transfusion.

• Pegcetacoplan

  • Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria who have haemolytic anaemi.
• Rilzabrutinib
• Ristoglogene Autogetemcel
• Rusfertide